Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderate to severe chronic hand eczema (CHE). Sold as Anzupgo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Delgocitinib (sold as Anzupgo), first approved Jul 23, 2025, with 0 new uses approved and 0 published complete response letters.
First approved: Jul 23, 2025
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $1.6M
First approved in the EU: Sep 19, 2024
First approved in Japan: Jan 23, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Anzupgo
Part D
$1.6M
New
494
Approvals in the EU (EMA)
First approved in the EU 10 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 66 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Corectim, new approvalDrugs with a new additional pediatric dosage and a drug in an additional dosage form indicated for the treatment of atopic dermatitis. · Japan Tobacco Inc. · Mar 23, 2021
Corectim, new ingredientA drug with a new active ingredient indicated for the treatment of atopic dermatitis. · Japan Tobacco Inc. · Jan 23, 2020 · Review report
Clinical Trials
8 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
